A recent study published in Proceedings of The National Academy of Sciences has identified a compound that could be used for the future treatment of Parkinson’s disease (PD). In the preliminary findings, the naturally-occurring compound squalamine was observed to both block α-synuclein aggregation in the brain and suppress the toxicity of these particles.
Restricted Content / Members Only
This content is available to members; it’s free to become a member. If you’re already a member, please login.